Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K12 | Q12852 | 20/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7765699 | 1.00 | MAP3K12 (0.48) | MAP3K12 | |
| SCHEMBL7758994 | 0.78 | MAP3K12 (0.33) | MAP3K12 | |
| SCHEMBL3782581 | 0.78 | MAP3K12 (0.49) | MAP3K12 | |
| SCHEMBL7765707 | 0.78 | MAP3K12 (0.49) | MAP3K12 | |
| SCHEMBL7762787 | 0.78 | MTOR (0.53) | MAP3K12 | |
| SCHEMBL3772835 | 0.78 | MTOR (0.53) | MAP3K12 | |
| SCHEMBL2708152 | 0.77 | MTOR (0.67) | — | |
| SCHEMBL2708158 | 0.77 | MTOR (0.67) | — | |
| SCHEMBL10239952 | 0.75 | MAP3K12 (0.78) | MAP3K12 | |
| SCHEMBL7763500 | 0.74 | PIK3CA (0.58) | MAP3K12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | GENENTECH, INC. (US) | 2010-12-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100331305-A1 | OXO-HETEROCYCLE FUSED PYRIMIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE | MTOR, PIK3CA, RICTOR | MAP3K12 40/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.